INO - Inovio Pharmaceuticals, Inc.
| Previous Close | 5.0000 |
| Open | 5.0000 |
| Bid | 4.900 x 1400 |
| Ask | 4.910 x 2900 |
| Day's Range | 4.8800 - 5.0300 |
| 52 Week Range | 3.6400 - 6.3000 |
| Volume | 200,938 |
| Avg. Volume | 852,435 |
| Market Cap | 467.678M |
| Beta (3Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.944 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
- Motley Fool•9 days ago
Can Inovio Pharmaceuticals Stock Keep Bounding Higher?
Inovio's stock has reclaimed a good chunk of its lost ground from last month's sell-off. Can it continue to surge?
- Zacks•13 days ago
Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
- Zacks•14 days ago
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
- Zacks•16 days ago
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
- Zacks•19 days ago
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
- Zacks•19 days ago
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
- Zacks•20 days ago
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
- Zacks•26 days ago
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
- Zacks•27 days ago
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
- Simply Wall St.•last month
Do Insiders Own Lots Of Shares In Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?
If you want to know who really controls Inovio Pharmaceuticals, Inc. (NASDAQ:INO), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk Read More...
- Zacks•2 months ago
Why Is Inovio (INO) Down 0.6% Since Last Earnings Report?
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•2 months ago
Inovio (INO) to Receive Milestone Payment From AstraZeneca
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
- GlobeNewswire•2 months ago
Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
Inovio Pharmaceuticals, Inc. (INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV). This open-label trial funded by MedImmune, the global biologics research and development arm of AstraZeneca, is sponsored by noted cancer researcher Dr. Michael Frumovitz, MD, MPH, of the MD Anderson Cancer Center in Houston, Texas, where the trial will be conducted as part of MD Anderson’s “Moon Shot” cancer initiative.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Ur Energy, SilverCrest Metals, Norwegian Cruise Line, Inovio Pharmaceuticals, Spok, and SunLink Health — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•2 months ago
Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.
- GlobeNewswire•2 months ago
Inovio Prepares for Growth & Commercialization With Leadership Appointments
Inovio Pharmaceuticals, Inc. (INO) made strategic leadership appointments in preparation for the commercialization of its lead asset and further development of its pipeline of immunotherapies and vaccines for cancer and challenging infectious diseases.
- Zacks•2 months ago
Merck Starts Rolling BLA Submission for Ebola Vaccine V920
Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.
- Zacks•2 months ago
Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet
Inovio Pharmaceuticals' (INO) Q3 loss betters estimates. Also, revenues match the consensus mark.
- Zacks•2 months ago
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of 15.63% and -9.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 08, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA.
- Simply Wall St.•3 months ago
What does Inovio Pharmaceuticals Inc’s (NASDAQ:INO) Balance Sheet Tell Us About Its Future?
Inovio Pharmaceuticals Inc (NASDAQ:INO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is INO Read More...
- GlobeNewswire•3 months ago
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 05, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment.
